Book a Demo Login

Case Study

Phase 3 Study in Ultra Rare Disease

How Adnexi accelerated Phase 3 enrollment through targeted digital screening and site matching for an ultra rare disease program.

Situation

A biopharmaceutical company developing innovative therapies for people with rare debilitating diseases sought to accelerate trial enrollment.

The Approach

  • Designed and implemented a compliant patient lead generation program targeting full enrollment
  • Directed patients to a clinical trial website with a digital prescreener
  • Gave authorized clinical trial personnel secure access to patient screening and enrollment data via the Adnexi Portal

Results

82
Patients completed pre-screen
46
Patients completed screening at an active site
22
Patients randomized in 12 months (~30% of trial)